Ann M. Arvin

Clinical Focus

• Infectious Diseases, Pediatric
• Pediatric Infectious Disease

Administrative Appointments

• Vice Provost and Dean of Research, Stanford University (2006 - present)
• Associate Dean of Research, Stanford University (2001 - 2006)

Honors and Awards

• Council, National Institute of Allergy and Infectious Diseases (2007-2011)
• Board on Life Sciences, National Academy of Sciences/National Research Council (2004-2010)
• Member, Institute of Medicine of the National Academies (2003)
• Member, Association of American Physicians (2002)
• John F. Enders Award, Infectious Diseases Society of America (2002)

Professional Education

Postdoctoral Advisees

Adel Mohamed Nour Mohamed Arfan, Stefan Oliver, Mike Reichelt, Nandini Sen, Li Wang, Yibing Wang

Graduate & Fellowship Program Affiliations

• Immunology
• Microbiology and Immunology
• Infectious Diseases

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

Our laboratory investigates the molecular virology of varicella zoster virus (VZV) infection, focusing on the functional roles of particular viral gene products in pathogenesis and virus-cell interactions in differentiated human cells in humans and in Scid-hu mouse models of VZV cell tropisms in vivo, and the immunobiology of VZV infections. Aspects of VZV infection are being investigated in the Scid-hu mouse models that have human skin, T cell and neural xenografts. Mutant strains of VZV are being developed from cosmids; recombinant strains are being tested for the effects of deletions, point mutations and linker insertions on T cell tropism and on latency. The role of VZV glycoproteins on the cytoskeletal rearrangements that occur to mediate syncytial formation is being investigated with deletion mutants. Viral protein kinases are being evaluated as virulence factors in vivo and in vitro with deletion mutants. The ultimate goal of these studies is to provide information relevant to developing new genetically engineered vaccines for VZV. In addition to basic research, our laboratory is involved with clinical vaccine studies to examine T-cell responses to VZV induced by varicella vaccine in healthy and immunocompromised individuals, T cell immunity to influenza viruses, and age-related effects on the development of measles immunity in infants.

Clinical Trials

• Ontogeny of Measles Immunity in Infants Recruiting

Publications

• Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry. Berarducci B, Rajamani J, Reichelt M, Sommer M, Zerboni L, Arvin AM. J Virol. 2009; 83 (1): 228-40
• The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. Reichelt M, Brady J, Arvin AM. J Virol. 2009; 83 (8): 3904-18
• Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis. Wang L, Sommer M, Rajamani J, Arvin AM. J Virol. 2009; 83 (15): 7560-72
• Anti-Glycoprotein H Antibody Impairs the Pathogenicity of Varicella-Zoster Virus in Skin Xenografts in the SCID Mouse Model. Vleck SE, Oliver SL, Reichelt M, Rajamani J, Zerboni L, Jones C, Zehnder J, Grose C, Arvin AM. J Virol. 2009
• Mutagenesis of varicella-zoster virus glycoprotein B: putative fusion loop residues are essential for viral replication, and the furin cleavage motif contributes to pathogenesis in skin tissue in vivo. Oliver SL, Sommer M, Zerboni L, Rajamani J, Grose C, Arvin AM. J Virol. 2009; 83 (15): 7495-506